WHOOP has closed a $575 million Series G round, catapulting its valuation to $10.1 billion and cementing its place at the top of the wearable health-tech market. Abbott, a heavyweight in traditional healthcare, joined the round and will take a seat on WHOOP’s board—an unmistakable signal that the line between medtech and consumer wearables is blurring fast.

This isn’t just another big check. The size of the round—one of the largest in digital health this year—underscores surging investor confidence in continuous health monitoring and subscription-driven business models. WHOOP’s rapid user and revenue growth, combined with its focus on both elite athletes and everyday consumers, has made it a standout in a crowded field.

Strategic Money, Strategic Moves

Abbott’s participation is more than symbolic. The company’s board seat gives WHOOP a direct channel into the regulated healthcare ecosystem, opening doors for clinical partnerships and potential FDA-cleared features down the line. For Abbott, it’s a front-row seat to consumer health data and a hedge against the slow pace of traditional medtech innovation.

WHOOP CEO Will Ahmed confirmed the funding will fuel continued hiring and product development. The company has already been on a hiring spree, scaling up engineering, data science, and customer support teams to keep pace with demand (MobiHealthNews).

Subscription Model, Sticky Revenue

Unlike most wearables that rely on hardware sales, WHOOP leans hard into subscriptions. Users pay monthly for continuous health monitoring, personalized insights, and coaching. That recurring revenue—plus the trove of longitudinal health data—gives WHOOP a defensible moat as Apple, Google, and Garmin ramp up their own health offerings.

The company hasn’t disclosed exact subscriber numbers, but industry estimates peg its user base in the millions, with annual revenue growth reportedly north of 50% year-over-year. The $10.1 billion valuation puts WHOOP in rarefied air, rivaling much larger hardware incumbents and signaling that investors see long-term upside beyond fitness tracking.

Wearables Surge, Healthcare Converges

The broader context: wearables are no longer just about steps and sleep. Demand for continuous, actionable health data is booming, fueled by consumers’ appetite for proactive wellness and chronic disease management. The market for wearable health devices is projected to reach $61 billion globally by 2027 (FierceBiotech).

WHOOP’s latest round comes as rivals like Oura, Fitbit, and Apple double down on health features. But WHOOP’s pure-play focus, athlete credibility, and now, a strategic healthcare partner, give it a unique edge as the sector matures.

What This Means

For founders in wearables and digital health, the message is clear: the market is rewarding companies that can prove real engagement and sticky, recurring revenue—not just flashy hardware. WHOOP’s success underscores the power of vertical integration (hardware, software, and services) and the growing importance of strategic alliances with incumbent healthcare players.

For the industry, this is a clear inflection point. The convergence of consumer wearables and regulated healthcare is accelerating, and the winners will be those who can bridge both worlds—delivering actionable insights to consumers while meeting the demands of clinical rigor and data privacy. Abbott’s board seat is a harbinger: expect more medtech giants to hunt for digital health partners, not just acquisitions but deep operational alliances.

The non-obvious second-order effect: as subscription-based health platforms like WHOOP amass richer longitudinal data, they’ll become indispensable not just to users, but to insurers, researchers, and pharma. The next wave isn’t just about monitoring—it’s about turning real-world health data into new clinical endpoints, risk models, and even digital therapeutics. WHOOP’s war chest just made that future a lot more plausible—and a lot more competitive.